Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: Results of a randomized clinical trial

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 633-643

  Patane, Michael A ^a   Cohen, Amy ^a   From, Stephen ^a   Torkildsen, Gail ^b   Welch, Donna ^c   Ousler III, George W ^c  

^a Jade Therapeutics Inc   (United States)

^b Andover Eye Associates   (United States)

^c Ora Inc   (United States)

Author keywords

Controlled adverse environment (CAE); Dry eye; Iontophoresis; Ocular protection index (OPI)

Indexed keywords

DEXAMETHASONE SODIUM PHOSPHATE; EGP 437; PLACEBO; UNCLASSIFIED DRUG;

ABNORMAL SENSATION; ADULT; AGED; ARTICLE; BLURRED VISION; CATARACT; CHEMOSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; EXPLORATORY RESEARCH; EYE DISCOMFORT; EYE IRRITATION; EYE PAIN; EYE PROTECTION; EYELID DISEASE; EYELID ERYTHEMA; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR FOREIGN BODY; IONTOPHORESIS; KERATITIS; LACRIMATION; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PROSPECTIVE STUDY; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOMATOLOGY; TEAR FILM; UNSPECIFIED SIDE EFFECT; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS;

EID: 79957467372     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S19349     Document Type: Article

References (34)

1. The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007; 5(2): 75-92.
2. The Epidemiology of Dry Eye Disease: Report of the Epidemiology Subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007; 5: 93-107.
3. Management and therapy of dry eye disease: Report of the Management and Therapy Subcommittee of the International Dry Eye Workshop. Ocul Surf. 2007; 5: 163-178.
4. ® [prescribing information]. Irvine, CA: Allergan, Inc; 2009.
5. Perry HD, Solomon R, Donnenfeld ED, et al. Valuation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008; 126: 1046-1050.
6. Walker PM, Lane KJ, Ousler GW 3rd, Abelson MB. Diurnal variation of visual function and the signs and symptoms of dry eye. Cornea. 2010; 29: 607-612.
7. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004; 137: 337-342.
8. Luo L, Li DQ, Corrales RM, Pflugfelder SC. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens. 2005; 31: 186-193.
9. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates pro- duction of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthal Vis Sci. 2004; 45: 4293-4301.
10. Huang AJW. Immunosuppressive therapy for ocular surface disorders. In: Dry Eye and Ocular Surface Disorders. Pflugfelder SC, Beuerman RW, Stern ME, editors. New York, NY. Marcel Dekker, Inc. 2004.
11. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J. 2006; 27: 413-426.
12. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern: Dry Eye Syndrome. San Francisco, CA: American Academy of Ophthalmology; 2008.
13. Chun DK, Shapiro A, Abelson MB. Ocular Pharmacokinetics. In: Principles and Practice of Ophthalmology, 3rd ed. Albert DM, Miller JW, editors. Toronto, ON. Elsevier, Inc; 2008.
14. Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv. 2006; 3: 275-287.
15. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Safety. 2008; 31: 127-141.
16. Von Sallmann L. Iontophoretic introduction of atropine and scopolamine into the rabbit eye. Arch Ophthalmol. 1943; 29: 711-719.
17. Hughes L, Maurice DM. A fresh look at iontophoresis. Arch Ophthalmol. 1984; 102: 1825-1829.
18. Jones RF, Maurice DM. New methods of measuring the rate of aqueous flow in man with fluorescein. Exp Eye Res. 1966; 5: 208-220.
19. Lam TT, Edward DP, Zhu XA, Tso MO. Transscleral iontophoresis of dexamethasone. Arch Ophthalmol. 1989; 107: 1368-1371.
20. Horwath-Winter J, Schmut O, Haller-Schober EM, et al. Iodide ion- tophoresis as a treatment for dry eye syndrome. Br J Ophthalmol. 2005; 89: 40-44.
21. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev. 2004; 56: 619-658.
22. Budavari S. Dexamethasone. In: The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals,14th ed. O'Neil MJ, editor. Whitehouse Station, NJ. Merck and Co; 2006.
23. Güngör S, Delgado-Charro MB, Ruiz-Perez B, et al. Trans-scleral ion- tophoretic delivery of low molecular weight therapeutics. J Controlled Release. 2010; 147: 225-231.
24. Ruiz-Perez B, Dowie T, Gee R, Isom P, Manzo M, Skokanova E. Trans- scleral delivery of a 12.4 kDa protein by ocular iontophoresis. Invest Ophthalmol Vis Sci. 2008; 49: 1813.
25. Ousler GW III, Gomes PJ, Welch D, Abelson MB. Methodologies for the study of ocular surface disease. Ocul Surf. 2005; 3: 143-154.
26. Ousler GW III, Anderson RT, Osborn KE. The effect of senofilcon A contact lenses compared to habitual contact lenses on ocular discomfort during exposure to a controlled adverse environment. Curr Med Res Opin. 2008; 24: 335-341.
27. González-García MJ, González-Sáiz A, et al. Exposure to a controlled adverse environment impairs the ocular surface of patients with minimally symptomatic dry eye. Invest Ophthalmol Vis Sci. 2007; 48: 4026-4032.
28. Ousler GW III, Wilcox KA, Gupta G, Abelson MB. An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetiriz- ine hydrochloride. Ann Allergy Asthma Immunol. 2004; 93: 460-464.
29. Crampton HJ, Ousler GW, Pflugfelder S, et al. Correlation of the Con- trolled Adverse Environment (CAE) model with a murine model of exper- imental dry eye in assessing the ability of topical doxycycline to prevent corneal barrier disruption. Invest Ophthalmol Vis Sci. 2007; 48: 402.
30. Ousler GW III, Hagberg KW, Schindelar M, et al. The Ocular Protection Index. Cornea. 2008; 27: 509-513.
31. Atkinson KA. An Introduction to Numerical Analysis, 2nd ed. New York: John Wiley & Sons; 1989.
32. Halhal M, Renard G, Courtois Y, et al. Iontophoresis: from the lab to the bed side. Exp Eye Res. 2004; 78: 751-757.
33. ® II Delivery System (EGDS): Safety and Tolerability in Healthy Adult Volunteers. Invest Ophthalmol Vis Sci. 2011; 52: 3224.
34. Patane M, Cohen A, Sugarman J, From S. Randomized, double-masked study of four iontophoresis dose levels of EGP-437 in non-infectious anterior segment uveitis subjects. Invest Ophthalmol Vis Sci. 2010; 51: 52-63.